To evaluate the phase I/II clinical study of LBL-024 in the treatment of patients with advanced malignant tumors
Agree to comply with the trial treatment plan and visit plan, voluntarily agree to sign the informed consent form;
18-75 years old (including boundary value), no gender limit in the I/IIa trial phase；18-80 years old (including boundary value), no gender limit in the IIb trial phase；
The expected survival time is at least 12 weeks
ECOG score is 0-1
Receiving other unmarketed clinical research drugs or treatments within 4 weeks before using the research drug for the first time;
Brain parenchymal metastases or meningeal metastases with clinical symptoms, which are not suitable for inclusion in the group by the investigator's judgment;
medical history of immunodeficiency including positive HIV antibody test;
Women who are pregnant or breastfeeding;